Sinovac Reports Bird Flu Vaccine Safe and Effective
Sinovac Biotech Ltd., (Beijing, China), has announced positive results of a completed Phase 2 clinical trial of its pandemic influenza (H5N1) whole viron inactivated vaccine.
Sinovac Biotech Ltd., (Beijing, China), has announced positive results of a completed Phase 2 clinical trial of its pandemic influenza (H5N1) whole viron inactivated vaccine. The stratified, randomized, double blind trial of the vaccine was designed to assess the safety and immunogenicity of the vaccine.
Sinovac received approval from the China State Food and Drug Administration (SFDA) in April 2007 to conduct Phase 1b and 2 trials of the H5N1 whole viron vaccine and Phase 1 and Phase 2 trials of the H5N1 split vaccine.
The Phase 2 trial of the H5N1 whole viron inactivated vaccine was conducted by Beijing Centers for Disease Control and Prevention. The preliminary results of the trials suggested that each of the three dosages could induce varying degrees of immune response. The trial results did not show any serious adverse reactions among volunteers.
Sinovac has also recently completed the Phase 1 clinical trial of the split H5N1 vaccine. The result of vaccinations on children, adults, and the elderly with candidate vaccines of different dosages indicated that the split H5N1 vaccine is safe for human use.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
